Comparison of in vitro maturation and in vitro fertilization for polycystic ovary syndrome patients-reply letter.

We thank for comments from Wu et al. (1) on our research (2) comparison between in vitro maturation (IVM) and in vitro fertilization (IVF) for polycystic ovary syndrome (PCOS).

Reviewer Wu et al. (1) said that we demonstrated that IVM might be a suitable option for PCOS in terms of cost and successful pregnancy rate. Whereas, the study had no results about cost comparison between IVM and IVF. We found this was a careless conclusion, and we suggest to correct discussion part of abstract to “Our study suggests that IVM had similar clinical effects compared to IVF in patients with PCOS”.

Secondly, they said we performed the sensitivity analysis only by removing Shavit et al.’s 2014 study (3) and only reported I2 value. Actually, we conducted sensitivity analysis by removing all the included articles one by one and only reported the biggest change one. According to his advice, we can change the sensitivity analysis to “We performed a sensitivity analysis by removing Shavit et al.’s 2014 study (3), and I2 changed from 48% to 39% and RR changed from 0.93 to 0.95, which indicated that the results of included articles were robust”.

Thirdly, they indicated that we made a mistake of live birth rate heterogeneity analysis. We do appreciate the advice, and we want to correct the heterogeneity analysis of live birth rate into “For live birth rate, seven studies with 1,234 patients were selected. Meta-analysis showed that, compared with the IVM group, the IVF group had a higher live birth rate (RR =0.82, 95% CI: 0.70–0.94, P=0.007, fixed-effects model), with insignificant heterogeneity (I2=26%).”

The article’s supplementary files as